Particle Therapy Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921917|
|出版日期||內容資訊||英文 95 Pages
|全球粒子治療市場:成長，趨勢，及預測(2020年∼2025年) Particle Therapy Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 95 Pages||
The global Particle Therapy market is expected to witness a CAGR of 8.6% during the forecast period. Certain factors that are driving the market growth include advantages offered by particle therapy and the growing global prevalence of cancer.
The number of people suffering from various cancers has been found to be a major driving factor for this market. Cancer is one of the major life-threatening diseases of our times. According to the WHO, cancer is the second leading cause of death, globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about one in six deaths are due to cancer. Approximately 70% of deaths from cancer occur in low and middle-income countries. According to the American Cancer Society, nearly 40,000 people in the United States were diagnosed with head and neck cancer, of which, 12,000 died in the year 2014 alone. Head and neck cancer account for nearly 5-6% of the cancer cases in the United States. It is the 15th most prevalent type of cancer in Europe, with nearly 56,000 cases diagnosed annually. Since particle therapies are used to treat cancer, the growing prevalence of the same is expected to be the major driver of the growth of this market.
Particle therapy is a cutting-edge area of external beam radiotherapy. It uses beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment.
Particle Therapy in Prostate Cancer is Expected to Hold a Significant Share Over the Forecast Period
Prostate cancer is the second most common type of cancer affecting the male reproductive system. About 80% of men who reach 80 years of age are diagnosed with it. As per the estimates provided by the American Cancer Society, in 2018, the United States witnessed over 164,690 new cases of prostate cancer, with over 29,430 related deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. One in every nine men is expected to be diagnosed with prostate cancer during his lifetime. Thus, considering the aforementioned factors, the concerned segment of the market is expected to witness high growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America dominated the global market studied, in 2018. Almost half of all cancer patients in the region, especially in the United States receive cancer treatment. The United States has the largest market for radiotherapy. The market is driven by factors, such as increasing incidences of cancer, replacements of older therapies with newer ones, and the availability of reimbursements for radiation therapy. A few states in the United States have passed laws compelling the personnel performing radiologic procedures to hold licenses. The changes in legislature and availability of reimbursement policies have led to incentivizing the providers to improve patient care and outcomes of treatment while controlling the costs. With large investments being made in R&D of innovative technologies for particle therapy, the market is expected to grow during the forecast period.
The global Particle Therapy market is highly competitive and consists of a number of major players. Companies like Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc., among others, hold the substantial market share in the Particle Therapy market.